Experimentation

This treatment regimen has been shown to improve recurrence-free survival, or RFS, and overall survival, or OS, for KIT+ GIST patients compared to 12 months of treatment. The US approval was based on...

KALYDECO is approved for people with CF ages 6 and older who have at least one copy of the G551D mutation in the cystic fibrosis transmembrane conductance regulator (CFTR) gene. KALYDECO was granted...

Both pivotal Phase III studies are fully recruited, and all patients have been treated, reached the primary endpoint and are in long-term follow-up. The study met all primary, secondary and tertiary efficacy endpoints....

HEADNOTE Three top Chinese tech companies-ALIBABA, BAIDU, and YOUKU-are remaking the country's moribund, hierarchical corporate culture with an injection of new ideas from the West. What is the sound of three hands clapping?...

In SHARP, VYTORIN 10/20 mg lowered LDL cholesterol in patients with moderate to severe chronic kidney disease, or CKD, and major vascular events were reduced in the treatment group compared to placebo. The...

The company has also announced the assignment of US co-promotion rights to AQUORAL, an FDA-cleared, prescription-only spray for the treatment of Xerostomia, or the medical term for dry mouth due to a lack...

The option agreement provides Navidea with exclusive rights for a period of up to six months to perform final due diligence and prepare the documentation necessary to enter into a definitive license agreement...

Keppra was previously approved in the US as adjunctive therapy for partial onset seizures in adults and children four years of age and older with epilepsy. The approval was based on data from...

Results from the trial, expected in 2014, could potentially impact atrial fibrillation treatment guidelines by providing further clinical evidence regarding the benefits of the Arctic Front system in treating a largely underserved patient...

GS-7340 is a novel prodrug of tenofovir, the active agent in Viread, or tenofovir disoproxil fumarate. In previous studies, GS-7340 has demonstrated the ability to provide greater antiviral efficacy at a dose that...

NovaDel Pharma, Inc., a specialty pharmaceutical company, has terminated its license agreements with Talon Therapeutics, Inc. (formerly Hana Biosciences, Inc. ) and Par Pharmaceutical Companies, Inc., for Zensana. Talon is a biopharmaceutical company,...

Acne is the most common skin disorder in the United States, affecting up to 50 million people, according to the American Academy of Dermatology. It's so widespread that by their mid-teens, more than...

PRINCETON, N.J. & WILMINGTON, Del. -- Bristol-Myers Squibb Company (NYSE: BMY) and AstraZeneca (NYSE: AZN) today announced that the U.S. Food and Drug Administration (FDA) has issued a complete response letter regarding the...

Stony Brook University has entered into a multiyear research partnership with the global pharmaceutical company Sanofi to develop a potential treatment for tuberculosis and other bacterial infections. The university didn't disclose the terms...

DUBLIN -- Research and Markets(http://www.researchandmarkets.com/research/ff135e/cervical_cancer_gl) has announced the addition of GlobalData 's new report "Cervical Cancer Global Clinical Trials Review, H2, 2011" to their offering. GlobalData's clinical trial report, Cervical Cancer Global Clinical...

Pharmacogenetic Patents Have the Potential to Extend Drug Candidate's Potential Commercial Exclusivity Period If Regulatory Approval Obtained BROOMFIELD, Colo. -- ARCA biopharma, Inc. (Nasdaq:ABIO), a biopharmaceutical company developing genetically targeted therapies for cardiovascular...

DUBLIN -- Research and Markets(http://www.researchandmarkets.com/research/657030/brain_cancer_globa) has announced the addition of GlobalData's new report "Brain Cancer Global Clinical Trials Review, H2, 2011" to their offering. GlobalData's clinical trial report, Brain Cancer Global Clinical Trials...

DUBLIN -- Research and Markets(http://www.researchandmarkets.com/research/966f32/chronic_myelocytic) has announced the addition of GlobalData's new report "Chronic Myelocytic Leukemia (CML) Global Clinical Trials Review, H2, 2011" to their offering. GlobalData's clinical trial report, Chronic Myelocytic Leukemia...

DUBLIN -- Research and Markets(http://www.researchandmarkets.com/research/5effb6/acute_myelocytic_l) has announced the addition of GlobalData 's new report "Acute Myelocytic Leukemia (AML) Global Clinical Trials Review, H2, 2011" to their offering. GlobalData's clinical trial report, Acute Myelocytic...